Literature DB >> 35301447

Epigenetic repression of gonadotropin gene expression via a GnRH-mediated DNA delivery system.

Lilach Pnueli1, Philippa Melamed2.   

Abstract

The reproductive axis is activated by gonadotropin-releasing hormone (GnRH), which stimulates the pituitary gonadotropes to secrete hormones that drive gonadal function and steroidogenesis. Thus repression of this axis, which is conserved across mammals and sexes, can reduce steroid levels and/or prevent reproduction. Steroid-dependent pathologies, including various cancers, are commonly treated with GnRH super-analogs which have long-term side-effects, while humane solutions for controlling reproduction in domestic and wild animal populations are lacking. GnRH-conjugated toxins are undergoing clinical trials for GnRHR-expressing cancer cells, and have been examined for gonadotrope ablation in animals, but showed low and/or transient effects and administration of toxins has many potential complications. Here we exploit GnRH targeting to gonadotropes to deliver DNA encoding an effector that induces gonadotropin gene repressive epigenetic modifications which are perpetuated over time. Several layers of specificity are endowed through targeting to GnRHR-expressing cells and due to local cleavage of the peptide packaging the DNA; the DNA-encoded effector is expressed and directed to the target genes by the DNA binding domain of a highly specific transcription factor. This design has multiple advantages over existing methods of shutting down the reproductive axis, and its modular design should allow adaptation for broad applications.
© 2022. The Author(s), under exclusive licence to Springer Nature Limited.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35301447     DOI: 10.1038/s41434-022-00325-6

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  56 in total

1.  Receptor mediated antiproliferative effects of the cytotoxic LHRH agonist AN-152 in human ovarian and endometrial cancer cell lines.

Authors:  S Westphalen; G Kotulla; F Kaiser; W Krauss; G Werning; H P Elsasser; A Nagy; K D Schulz; C Grundker; A V Schally; G Emons
Journal:  Int J Oncol       Date:  2000-11       Impact factor: 5.650

Review 2.  GnRH receptors in cancer: from cell biology to novel targeted therapeutic strategies.

Authors:  Patrizia Limonta; Marina Montagnani Marelli; Stefania Mai; Marcella Motta; Luciano Martini; Roberta M Moretti
Journal:  Endocr Rev       Date:  2012-07-09       Impact factor: 19.871

3.  Effective targeted chemotherapy using AEZS-108 (AN-152) for LHRH receptor-positive pancreatic cancers.

Authors:  Carsten Gründker; Jennifer Ernst; Madita D Reutter; B Michael Ghadimi; Günter Emons
Journal:  Oncol Rep       Date:  2011-06-07       Impact factor: 3.906

Review 4.  Advances in therapeutic peptides targeting G protein-coupled receptors.

Authors:  Anthony P Davenport; Conor C G Scully; Chris de Graaf; Alastair J H Brown; Janet J Maguire
Journal:  Nat Rev Drug Discov       Date:  2020-03-19       Impact factor: 84.694

5.  Effects of a GnRH cytotoxin on reproductive function in peripubertal male dogs.

Authors:  Barry A Ball; Khalida Sabeur; Terry Nett; Irwin K M Liu
Journal:  Theriogenology       Date:  2006-02-28       Impact factor: 2.740

6.  Receptors for luteinizing hormone-releasing hormone (GnRH) as therapeutic targets in triple negative breast cancers (TNBC).

Authors:  C W Kwok; O Treeck; S Buchholz; S Seitz; O Ortmann; J B Engel
Journal:  Target Oncol       Date:  2014-10-09       Impact factor: 4.493

7.  Targeted chemotherapy for triple-negative breast cancers via LHRH receptor.

Authors:  Crispin Föst; Francesca Duwe; Martin Hellriegel; Stefan Schweyer; Günter Emons; Carsten Gründker
Journal:  Oncol Rep       Date:  2011-02-17       Impact factor: 3.906

Review 8.  Targeting of Peptide Cytotoxins to LHRH Receptors For Treatment of Cancer.

Authors:  Jorg B Engel; Hans-Rudolf Tinneberg; Ferenc G Rick; Enniko Berkes; Andrew V Schally
Journal:  Curr Drug Targets       Date:  2016       Impact factor: 3.465

Review 9.  GnRH and GnRH receptors in the pathophysiology of the human female reproductive system.

Authors:  Roberto Maggi; Anna Maria Cariboni; Marina Montagnani Marelli; Roberta Manuela Moretti; Valentina Andrè; Monica Marzagalli; Patrizia Limonta
Journal:  Hum Reprod Update       Date:  2015-12-29       Impact factor: 15.610

10.  Novel LHRH-receptor-targeted cytolytic peptide, EP-100: first-in-human phase I study in patients with advanced LHRH-receptor-expressing solid tumors.

Authors:  Kelly K Curtis; John Sarantopoulos; Donald W Northfelt; Glen J Weiss; Kerry M Barnhart; John K Whisnant; Carola Leuschner; Hector Alila; Mitesh J Borad; Ramesh K Ramanathan
Journal:  Cancer Chemother Pharmacol       Date:  2014-03-08       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.